Cibus (CBUS) Total Liabilities (2016 - 2026)
Cibus (CBUS) posted Total Liabilities of $283.2 million for Q4 2025, up 1.8% sequentially from $278.2 million in Q3 2025, and up 12.28% YoY from $252.2 million in Q4 2024.
Cibus (CBUS) Total Liabilities (2016 - 2026) Analysis & Trends
Cibus has reported Total Liabilities for 10 years, with the latest figure at $283.2 million in Q4 2025.
- Quarterly Total Liabilities rose 12.28% year-over-year to $283.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $283.2 million (up 12.28% YoY) and the FY2025 annual result came in at $283.2 million, up 12.28% from the prior year.
- Total Liabilities rose to $283.2 million in Q4 2025 per CBUS's latest filing, from $278.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $283.2 million in Q4 2025 and troughed at $15.2 million in Q4 2022.
- A 5-year average of $142.4 million and a median of $198.4 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 34.14% in 2022, then jumped 1257.1% in 2023.
- Over 5 years, Total Liabilities stood at $23.1 million in 2021, then tumbled by 34.14% to $15.2 million in 2022, then surged by 1257.1% to $206.1 million in 2023, then advanced by 22.38% to $252.2 million in 2024, then increased by 12.28% to $283.2 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $283.2 million, $278.2 million, and $271.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 10.03 Bn |
| 10 | Cibus | 134.81 Mn | 114.38 Mn | - | 298.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298.65 Mn |
| Dec 31, 2025 | 283.22 Mn |
| Sep 30, 2025 | 278.20 Mn |
| Jun 30, 2025 | 271.72 Mn |
| Mar 31, 2025 | 261.09 Mn |
| Dec 31, 2024 | 252.24 Mn |
| Sep 30, 2024 | 246.99 Mn |
| Jun 30, 2024 | 246.31 Mn |
| Mar 31, 2024 | 213.21 Mn |
| Dec 31, 2023 | 206.12 Mn |
| Sep 30, 2023 | 203.74 Mn |
| Jun 30, 2023 | 193.09 Mn |
| Mar 31, 2023 | 17.62 Mn |
| Dec 31, 2022 | 15.19 Mn |
| Sep 30, 2022 | 17.86 Mn |
| Jun 30, 2022 | 18.26 Mn |
| Mar 31, 2022 | 23.42 Mn |
| Dec 31, 2021 | 23.06 Mn |
| Sep 30, 2021 | 23.70 Mn |
| Jun 30, 2021 | 25.88 Mn |